← Back to Search

Urolift for Enlarged Prostate

N/A

Waitlist Available

Led By Bilal Chughtai, MD

Research Sponsored by Weill Medical College of Cornell University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

Study Summary

This trial is testing a new minimally invasive therapy to see if it can reduce the acute and long-term urinary toxicity side effects from radiation therapy.

Eligible Conditions

Enlarged Prostate

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at baseline and one year post treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at baseline and one year post treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline and one year post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in IIEF score through study completion, an average of 1 year

Change in IPSS scores from baseline and one year post treatment

Change in MSHQ through study completion, an average of 1 year

+3 more

Secondary outcome measures

Change in medication usage through study completion, an average of 1 year

Trial Design

1Treatment groups

Experimental Treatment

Group I: UroliftExperimental Treatment1 Intervention

This is a single-arm study involving 1 year of follow-up. Study intervention involves a one-time administration of Urolift prior to SBRT for prostate cancer treatment.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NeoTract, Inc.Industry Sponsor

10 Previous Clinical Trials

3,380 Total Patients Enrolled

TeleflexIndustry Sponsor

21 Previous Clinical Trials

4,825 Total Patients Enrolled

Weill Medical College of Cornell UniversityLead Sponsor

1,054 Previous Clinical Trials

1,316,532 Total Patients Enrolled

Media Library

Urolift Clinical Trial Eligibility Overview. Trial Name: NCT05148156 — N/A

Enlarged Prostate Research Study Groups: Urolift

Enlarged Prostate Clinical Trial 2023: Urolift Highlights & Side Effects. Trial Name: NCT05148156 — N/A

Urolift 2023 Treatment Timeline for Medical Study. Trial Name: NCT05148156 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I meet the criteria to partake in this research endeavor?

"The current recruitment drive is seeking 20 willing individuals, aged between 40 and 99 years old, who possess adenoma of the prostate. Additionally, these patients must be eligible for Urolift surgery and lack a middle lobe in order to qualify."

Answered by AI

How many participants can be accepted into this experiment?

"Yes, clinicaltrials.gov hosts data showing that this study is actively seeking participants. This research was first posted on December 15th 2021 and its most recent update occurred July 6th 2022. The investigators are looking to recruit 20 individuals from one location."

Answered by AI

Is there an age restriction in place for the participants of this trial?

"This clinical trial requires that interested patients are between the ages of 40 to 99. In contrast, there are 28 studies for minors under 18 and 105 trials available for those aged over 65."

Answered by AI

Are individuals being accepted for participation in this study at present?

"As indicated on clinicaltrials.gov, this research programme is still seeking participants. It was initially posted around December 15th 2021 and has had a recent update as of July 6th 2022."

Answered by AI

Recent research and studies

International braz j urolJournal

The Role and Importance of SBRT in Prostate Cancer

Cihan, Yasemin. 2018. “The Role and Importance of SBRT in Prostate Cancer”. International Braz J Urol. FapUNIFESP (SciELO). doi:10.1590/s1677-5538.ibju.2018.0484.

Radiation OncologyJournal

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men with Large Prostates (≥50 Cm3)

Janowski, Einsley, Leonard N Chen, Joy S Kim, Siyuan Lei, Simeng Suy, Brian Collins, John Lynch, Anatoly Dritschilo, and Sean Collins. 2014. “Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men with Large Prostates (≥50 Cm3)”. Radiation Oncology. Springer Science and Business Media LLC. doi:10.1186/s13014-014-0241-3.

Practical Radiation OncologyJournal

High-dose-rate Stereotactic Body Radiation Therapy for Postradiation Therapy Locally Recurrent Prostatic Carcinoma: Preliminary Prostate-specific Antigen Response, Disease-free Survival, and Toxicity Assessment

Fuller, Donald B., James Wurzer, Reza Shirazi, Stephen S. Bridge, Jonathan Law, and George Mardirossian. 2015. “High-dose-rate Stereotactic Body Radiation Therapy for Postradiation Therapy Locally Recurrent Prostatic Carcinoma: Preliminary Prostate-specific Antigen Response, Disease-free Survival, and Toxicity Assessment”. Practical Radiation Oncology. Elsevier BV. doi:10.1016/j.prro.2015.04.009.

Urologic Clinics of North AmericaJournal